Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 June 2024 | Story André Damons | Photo André Damons
Prof Victor Houliston
Prof Victor Houliston, Research Professor in the Department of English, is an A-rated researcher at the University of the Free State (UFS).

The University of the Free State (UFS) has added another National Research Foundation (NRF) A1-rated researcher to its ranks with the appointment of Prof Victor Houliston, Research Professor in the Department of English. This brings the number of the university’s A1-rated researchers to three.

The university also boasts the first A2 rating in the field of arts in the person of Prof Willem Boshoff, a senior professor in the Department of Fine Arts within the Faculty of The Humanities and one of South Africa's foremost contemporary artists. The other scholars with an A1 rating are Prof Maxim Finkelstein, the distinguished Professor at the Department of Mathematical Statistics and Actuarial Science, and Prof Melanie Walker, Distinguished Research Professor and National Research Foundation (NRF) Chair in Higher Education and Human Development.

The A rating is for researchers regarded as world leaders in their fields. Prof Houliston received his rating in 2022 – three years after retiring from the University of the Witwatersrand (Wits).

Consistent research output

Prof Houliston, who is an authority on early modern British and Irish Catholic studies (religion and politics) and has also published on John Donne (especially his prose works and sermons) and Renaissance rhetoric, says there is no formula for receiving an A1 rating.

“The definition of an A-rated scholar is someone who has achieved a certain reputation in their field internationally. That comes from a consistent research output, building up a portfolio of work in a particular field and moving the debate along, so that you become the go-to person on that subject.

“There is that sense of focus and some shifting of the picture or debate or understanding in your field. In science, the evaluation of a person's standing is more straightforward; in the humanities, research has a more subjective element so one's work is more vulnerable to criticism. In my case, as my research has evolved from English literature into historical studies, it has entailed archival and linguistic groundwork which makes it a little more objective,” says Prof Houliston.

The importance of Robert Persons

It is hard to say whether he chose his specialism, or his specialism chose him: an unexpected request for help from Guy Butler in 1988 led to his investigating the life and career of Robert Persons, an English Jesuit from the time of Queen Elizabeth I. Over the intervening 30 years, this Catholic activist has become widely recognised as one of the most important figures in early modern European history.

Prof Houliston started with a re-interpretation of Persons' published works, culminating in a 2007 monograph, Catholic Resistance in Elizabethan England. He is now editing Persons' extensive multilingual correspondence, as the leader of an international team of experts. The second volume was published earlier this year, with a third in preparation. He is also working with a team of South African classicists to translate Persons' Latin publications.

"As with most research, we work from the known to the unknown, pushing back further into the primary material – the archive."

Prof Houliston says that as a researcher, one must jealously guard one's time, which is difficult because the demands of teaching and administration have become more burdensome. Most academics show great commitment and idealism when it comes to teaching, so they are reluctant to leave students to their own devices. Ironically, this often leads those who are on the A-rating trajectory to take refuge in specialised institutes or centres of excellence and stop teaching, which can be a loss to students.

Given space to do research 

“Lecturers at a university such as the UFS, with its goal of increasing its research productivity, need space to do research. Bureaucracy may have to retract a bit. Lecturers themselves have to learn where to draw the line,” he says.

"This may appear selfish, but it enhances the learning environment. If you were to ask students if they preferred to be in a university where high-quality research is taking place, they would likely say, 'Yes. That gives my degree greater credibility. I would want to feel that those who are teaching me are contributing to the increase of knowledge’.”

His advice to emerging researchers is to follow the advice of Stephen Covey, author of The 7 Habits of Highly Effective People: conduct a weekly review of how they are managing to integrate research into their daily life as academics. Most lecturers are in a position where they only do research during vacations, but they can challenge themselves to carve out more regular times for research.

No slowing down

“That idea of constant review is important so that you are always moving forward. Many people just give up, because research is more challenging than, say, answering your emails, and you need energy and time. So, if you can reduce that start-up cost by doing a little every day, and preferably at the beginning of every day, it will make all the difference.

“The UFS, and especially heads of departments, can help to create a culture where scholars and researchers feel part of an interactive community. We need to move beyond the system to a sense of vocation. We have a vocation as university lecturers, professors and scholars, and everything else is secondary to the pursuit of knowledge. The system is merely a tool,” says Prof Houliston.

With multiple large-scale research projects on the go, as well as workshops and writing retreats, he is now busier than ever, with no plans for slowing down. He says: “I recently hosted a workshop for colleagues planning to apply for rating, to optimise their applications. One of my briefs is to enhance the research communities within the English department and the Faculty of Humanities in general, and especially amongst younger researchers.”

You could say he is speeding up. He recently completed a master’s degree in creative writing. "It's never too late to discover how many bad writing habits I have developed over the years!" 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept